1-4 of 4
Bin Zhang
Close
Sort by
Journal Articles

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

Clinical Trials & Observations
Li-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, Ming-Zhi Zhang, Zhi-Ming Li, Chun-Yan Ji, Wei Xu, Ting Liu, Bing Xu, Xin Wang, Su-Jun Gao, Hui-Lai Zhang, Yu Hu, Yan Li, Ying Cheng, Hai-Yan Yang, Jun-Ning Cao, Zun-Min Zhu, Jian-Da Hu, Wei Zhang, Hong-Mei Jing, Kai-Yang Ding, Xiang-Yang Zhang, Ren-Bin Zhao, Bin Zhang, Ya-Min Tian, Yong-Ping Song, Yu-Qin Song, Jun Zhu
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4349–4357.
https://doi.org/10.1182/bloodadvances.2022009168
Published: 2023
Includes: Supplemental data
Journal Articles

Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII

Yuan Zhang, Zhigang Liu, Bin Zhang
Journal: Blood Advances
Blood Adv (2023) 7 (7): 1286–1296.
https://doi.org/10.1182/bloodadvances.2022008788
Published: 2023
Includes: Supplemental data
Journal Articles

Altered phenotype in LMAN1-deficient mice with low levels of residual LMAN1 expression

Lesley A. Everett, Rami N. Khoriaty, Bin Zhang, David Ginsburg
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5635–5643.
https://doi.org/10.1182/bloodadvances.2020002523
Published: 2020
Includes: Supplemental data
Journal Articles

Analysis of MCFD2- and LMAN1-deficient mice demonstrates distinct functions in vivo

Min Zhu, Chunlei Zheng, Wei Wei, Lesley Everett, David Ginsburg, Bin Zhang
Journal: Blood Advances
Blood Adv (2018) 2 (9): 1014–1021.
https://doi.org/10.1182/bloodadvances.2018018317
Published: 2018